In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2000 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer. 

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The lymphatic system helps filter out bacteria and is important in fighting disease. Every so often, the lymph vessels widen into lymph nodes. In lymphoma, some of the cells in the lymph system multiply uncontrollably - if all the cells are the same they are called malignant or cancerous. Lymphoma is differentiated by the type of cell that multiplies and how the cancer presents itself. 

The two main groups of lymphoma in humans are Hodgkin's Disease (characterized by the growth of Reed-Sternberg cells) and the Non-Hodgkin's Lymphomas (NHL). NHL's are also classified according to their cell type. Effecting either B-cells or T-cells. A large number of NHLs are classified as B-cell NHLs. According to the American Cancer Society, 60 900 new cases of lymphoma were predicted in 2002 in the U.S; 53 900 of which were Non-Hodgkin and 7 000 Hodgkin Lymphomas. Another 7000 Chronic Lymphatic Leukemias were predicted. The number of deaths were predicted to 25 800, 1 400, 24 400, and 4 500 respectively. The emerging non-Hodgkins lymphoma therapeutics market generated $1.14 billion in revenue in 2000, according to Frost & Sullivan. Total revenue for drugs treating all stages of non-Hodgkins lymphoma should grow to $4.7 billion by 2008. 

Patters and Trends in Lymphoma R&D is one of the most comprehensive and up to date information sources currently available in the lymphoma R&D arena. Information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mecanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current lymphoma pipeline.

Size: 243 pages

Release date: Dec 16, 2003 

Publisher: BioSeeker 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker.html#a448